Watterson DM - Search Results

1

Human amyloid beta-induced neuroinflammation is an early event in neurodegeneration.

Craft JM, Watterson DM, Van Eldik LJ. Craft JM, et al. Among authors: watterson dm. Glia. 2006 Apr 1;53(5):484-90. doi: 10.1002/glia.20306. Glia. 2006. PMID: 16369931

2

Discovery of a new class of synthetic protein kinase inhibitors that suppress selective aspects of glial activation and protect against beta-amyloid induced injury: a foundation for future medicinal chemistry efforts focused on targeting Alzheimer's disease progression.

Watterson DM, Velentza AV, Zasadzki M, Craft JM, Haiech J, Van Eldik LJ. Watterson DM, et al. J Mol Neurosci. 2003;20(3):411-23. doi: 10.1385/JMN:20:3:411. J Mol Neurosci. 2003. PMID: 14501026

3

Aminopyridazines attenuate hippocampus-dependent behavioral deficits induced by human beta-amyloid in a murine model of neuroinflammation.

Craft JM, Van Eldik LJ, Zasadzki M, Hu W, Watterson DM. Craft JM, et al. Among authors: watterson dm. J Mol Neurosci. 2004;24(1):115-22. doi: 10.1385/JMN:24:1:115. J Mol Neurosci. 2004. PMID: 15314259

4

Aminopyridazines inhibit beta-amyloid-induced glial activation and neuronal damage in vivo.

Craft JM, Watterson DM, Frautschy SA, Van Eldik LJ. Craft JM, et al. Among authors: watterson dm. Neurobiol Aging. 2004 Nov-Dec;25(10):1283-92. doi: 10.1016/j.neurobiolaging.2004.01.006. Neurobiol Aging. 2004. PMID: 15465624

5

Enhanced susceptibility of S-100B transgenic mice to neuroinflammation and neuronal dysfunction induced by intracerebroventricular infusion of human beta-amyloid.

Craft JM, Watterson DM, Marks A, Van Eldik LJ. Craft JM, et al. Among authors: watterson dm. Glia. 2005 Aug 15;51(3):209-16. doi: 10.1002/glia.20194. Glia. 2005. PMID: 15810011

6

Interleukin 1 receptor antagonist knockout mice show enhanced microglial activation and neuronal damage induced by intracerebroventricular infusion of human beta-amyloid.

Craft JM, Watterson DM, Hirsch E, Van Eldik LJ. Craft JM, et al. Among authors: watterson dm. J Neuroinflammation. 2005 Jun 20;2:15. doi: 10.1186/1742-2094-2-15. J Neuroinflammation. 2005. PMID: 15967035 Free PMC article.

7

Validation of the neuroinflammation cycle as a drug discovery target using integrative chemical biology and lead compound development with an Alzheimer's disease-related mouse model.

Hu W, Ralay Ranaivo H, Craft JM, Van Eldik LJ, Watterson DM. Hu W, et al. Among authors: watterson dm. Curr Alzheimer Res. 2005 Apr;2(2):197-205. doi: 10.2174/1567205053585828. Curr Alzheimer Res. 2005. PMID: 15974919

8

Neuroinflammation: a potential therapeutic target.

Craft JM, Watterson DM, Van Eldik LJ. Craft JM, et al. Among authors: watterson dm. Expert Opin Ther Targets. 2005 Oct;9(5):887-900. doi: 10.1517/14728222.9.5.887. Expert Opin Ther Targets. 2005. PMID: 16185146 Review.

9

Glia as a therapeutic target: selective suppression of human amyloid-beta-induced upregulation of brain proinflammatory cytokine production attenuates neurodegeneration.

Ralay Ranaivo H, Craft JM, Hu W, Guo L, Wing LK, Van Eldik LJ, Watterson DM. Ralay Ranaivo H, et al. Among authors: watterson dm. J Neurosci. 2006 Jan 11;26(2):662-70. doi: 10.1523/JNEUROSCI.4652-05.2006. J Neurosci. 2006. PMID: 16407564 Free PMC article.

10

Barriers to Alzheimer disease drug discovery and development in academia.

Van Eldik LJ, Koppal T, Watterson DM. Van Eldik LJ, et al. Among authors: watterson dm. Alzheimer Dis Assoc Disord. 2002;16 Suppl 1:S18-28. doi: 10.1097/00002093-200200001-00004. Alzheimer Dis Assoc Disord. 2002. PMID: 12070358 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

181 results

Search Page

Filters